TransGenic Group Inc (TransGenic) offers drug discovery support services, specializing in genetically modified animals and genome editing technologies. It also provides advisory services in business succession, revitalization, and mergers & acquisitions (M&A). The company operates through two business segments: Drug Discovery Support Business and Investment and Consulting Business.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

TransGenic is engaged in research and development across a range of fields to contribute to the future and realise healthier and more fulfilling lives globally. The company is promoting R&D of products and services central to its future business. Key initiatives include the development of highly versatile disease model mice using gene modification technology, the introduction and R&D of new drugs, and the commercialisation of "liver-humanized mice" for precise non-clinical trials. Additionally, the company has begun offering contract services for "medium-term carcinogenicity testing" and is developing test systems for short-term carcinogenicity testing using various administration routes. It undergoes operations through a subsidiary, Transgenic Inc., which is the core company of the drug discovery support business. This unit is responsible for developing highly competitive genotoxicity testing using genetically modified mice, conducting non-clinical pharmacology testing, and providing contract clinical trial services for pharmaceuticals and food products. In FY2025, the company invested JPY83.3 million in its R&D activities, which increased by 35.8% YoY and as a percentage of its revenue stood at 0.06%.